May. 12 at 5:58 PM
$OKLO Looking forward to seeing the upward target revisions tomorrow that take into account (1)
$NVDA partnership, (2) PDC approval in record time- 15 days, (3) Announced 7/4 criticality target for Groves, something that no other public SMR company is able to do, (4) Initial revenue via radioisotopes and the increased TAM through the space sector, (5) inclusion within Project Genesis for the Pluto reactor.
Likely to see upward revisions of PTs
$110 -
$150.
$SMR $NNE $XE